Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
18F-DCFPyL Imaging to Assess SBRT Response in Prostate Cancer
NCT05155046Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Aug 2022
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of piflufolastat f 18 in prostate cancer (PCa), sponsored by National Cancer Institute. Primary endpoint: Imaging response to treatment. Started Aug 2022; status: recruiting.
02
Drugs
piflufolastat f 18
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05155046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05155046.